|
Feb 09
|
|
—
|
AVOID
|
Dr. Scott Gottlieb
Former FDA Commissioner; Board Member (Pfizer, Illumina, UnitedHealth); Partner at NEA (Venture Capital)
|
Investment capital is fleeing the vaccine research sector. Gottlieb notes that research into vaccines for Epstein-Barr Virus (EBV), MS, and cancer prevention is being pulled back. The political and regulatory environment has become hostile. It is increasingly difficult to get vaccines through the FDA due to policy changes, and even if approved, the CDC is showing reluctance to recommend them due to anti-vaccine sentiment. Gottlieb states that as a Venture Capital partner, he sees it is "very hard to get a new vaccine program funded" right now. A shift in political sentiment or a new public health crisis forcing a regulatory pivot. |
CNBC
Dr. Scott Gottlieb on Novo Nordisk vs. Hims &...
|